Compare New Era Energy & Digital Inc. Common Stock (NUAI) vs Royalty Pharma plc Class A Ordinary Shares (RPRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
New Era Energy & Digital Inc. Common Stock vs Royalty Pharma plc Class A Ordinary Shares — how do they compare? New Era Energy & Digital Inc. Common Stock trades at $4.7 (market cap $583.45M), while Royalty Pharma plc Class A Ordinary Shares trades at $56.88 (market cap $25.27B). The key difference: Royalty Pharma plc Class A Ordinary Shares is far larger — about 43.3× New Era Energy & Digital Inc. Common Stock's market cap, and Royalty Pharma plc Class A Ordinary Shares pays a 1.66% dividend while New Era Energy & Digital Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold New Era Energy & Digital Inc. Common Stock for 0 Days and Royalty Pharma plc Class A Ordinary Shares for 1 Days on average.
| NUAI | RPRX | |
|---|---|---|
Market Cap | $583.45M | $25.27B |
Volume | 17,217,412 | 3,671,183 |
Sector | Technology | Health |
52-Week High | $8.06 | $63.96 |
52-Week Low | $2.35 | $35.44 |
Typical Hold Time | 0 Days | 1 Days |
Enterprise Value | $528.80M | $32.50B |
Dividend Yield | — | 1.66% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About New Era Energy & Digital Inc. Common Stock
New Era Energy & Digital develops large-scale data centers in energy-rich U.S. markets for AI training and inference workloads. Its Texas Critical Data Centers project in the Permian Basin combines modular deployment with flexible power solutions.
Read more on NUAI →About Royalty Pharma plc Class A Ordinary Shares
Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →
